Study: Japan Reaches Biosimilar Patient Access Faster Than USA, EU
Patient access to biosimilars in Japan reaches commercial markets faster than in the United States or the European Union despite persistent regulatory approval lags, according to a study published on November 21, 2026 in Naunyn-Schmiedeberg’s Archives of Pharmacology.
The research, titled “From regulatory approval to patient access: A comparative analysis of biosimilar market entry timelines in Japan, the USA, and the EU,” was authored by Miya Kawasaki, Yuka Saino, Anri Nishizawa, Aya Hariu, and Ryosuke Kuribayashi, according to PubMed.
Authors Miya Kawasaki, Yuka Saino, Anri Nishizawa, and Ryosuke Kuribayashi are affiliated with the Office of Cellular and Tissue-Based Products at the Pharmaceuticals and Medical Devices Agency in Tokyo, Japan, while Ryosuke Kuribayashi is also associated with the agency’s Office of Regulatory Science Research.
The study highlights that biosimilar approval lag and biosimilar loss—also referred to as the biosimilar void—remain important challenges particularly in Japan compared with the USA and the EU.
Investigators evaluated biosimilar approval lag, market entry lag, and patient access time, which was defined as the interval between regulatory approval and first commercial launch. The initial commercial release functioned as the primary quantifiable indicator for patient access, rather than serving as an assessment of how frequently biosimilars were subsequently utilized in clinical settings.
Analyses were conducted using publicly available data from Japan’s Pharmaceuticals and Medical Devices Agency, the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA), supplemented by company press releases.
The findings revealed that the median patient access time was shortest in Japan at 6 months, compared with 15 months in the USA and 17 months in the EU. Even with a continuous delay in approvals, the availability of biosimilars for patients in Japan was often on par with, or ahead of, availability in the USA and the EU, primarily due to the reduced time between approval and market introduction.
The Pharmaceuticals and Medical Devices Agency functions as an Independent Administrative Institution tasked with ensuring the safety, efficacy, and quality of medical products in Japan. Beyond its regulatory review role, the agency manages a unique victim compensation program that provides financial support for medical costs and lost wages to individuals who experience injury or disability resulting from the use of medical products, as well as to those infected with HIV through blood transfusions.
To modernize its operations, the organization shifted its submission process in 2017 by adopting the International Council for Harmonisation Electronic Common Technical Document format for all electronic regulatory filings.
The authors concluded that regulatory approval timing alone is insufficient to assess patient access to biosimilars. To guarantee that patients can access treatments in a timely manner, it is necessary to implement a holistic strategy that combines post-approval procedures—such as reimbursement, pricing, and market entry—alongside synchronized initiatives throughout the entire lifespan of a biosimilar.